News and Announcements
Atomo Diagnostics Receives CE Mark Approval for Both HIV Self-Test & HIV Professional Products
- Published January 11, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- CE Marking granted for Atomo HIV Self Test and AtomoRapid HIV for professional use
- Approval from the World Health Organisation’s Expert Review Panel for Diagnostics for Atomo HIV Self Test
- Atomo HIV Self Test received approval from Kenya Ministry of Health
- AtomoRapid HIV received approval from Nigerian Ministry of Health
- Two OEM agreements signed for the licencing and sale of Atomo’s device technology
- Grand Challenges Canada invested US$1 million
- Doris-Ann Williams MBE, CEO of the British IVD Association, joined the Board of Atomo
Atomo Diagnostics is a world leader in the device, design, development and commercialisation of innovative, user-friendly, rapid test products. The recipient of multiple international awards for innovation and design, Atomo’s all-in-one AtomoRapid™ handheld device platforms make it easy to test and screen for a range of infectious diseases and chronic conditions. Unlike standard, multi-component rapid test kits, AtomoRapid™ platforms integrate features and functionality.
The company has also attracted grant funding from Commercialisation Australia, the NSW Medical Devices Fund, Austrade and the Bill and Melinda Gates Foundation, as well as securing significant financial support from the Global Health Investment Fund.
During 2017, Atomo Diagnostics was granted CE Marking for both its HIV Self Test and HIV professional use products. Atomo is now finalising a number of strategic commercialisation agreements with key partners to launch these products across global markets in 2018.
The Atomo HIV Self Test has also received approval from the World Health Organisation’s Expert Review Panel for Diagnostics (ERP-D). This allows the product to be procured by organisations eligible for Global Fund and UNITAID funding. There are currently more than 50 million HIV rapid tests procured annually using Global Fund and UNITAID funds.
In addition to growing sales channels for Atomo’s own range of commercial products, the company also provides its award-winning products as an OEM offering for other diagnostic companies looking to improve their product offerings or enter self-test markets. In 2017, two major OEM agreements were completed with global partners for the licensing and distribution of products with several more agreements anticipated for completion during 2018.
About Atomo Diagnostics
Atomo Diagnostics is a multi-award winning and rapidly growing medical device company that has developed and commercialised AtomoRapid™, the world’s first integrated device for blood based immunoassay rapid diagnostic testing (RDTs) in point of care settings.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
